Prostate cancer drug shows ‘promising’ mechanism of action
Pharmaceutical company Promontory Therapeutics has completed enrolment of its Phase II clinical trial of lead therapeutic candidate, PT-112, in patients with late-line metastatic castration-resistant prostate cancer (mCRPC). The study is evaluating PT-112 in patients who have been treated with at least three prior life-prolonging therapies… Read More
